



Gelclair

Literary Review



July to October 2014

Title	Publication	Date	Overview
Head and neck cancer relapse after chemoradiotherapy correlates with CD163 + macrophages in primary tumour and CD11b + myeloid cells in recurrences	British Journal of Cancer, Vol. 111, No. 8, pages 1509-1518.	14 October	Investigation of the prognostic role of tumour-associated macrophages in patients with head and neck squamous cell carcinoma (HNSCC) treated with definitive chemoradiotherapy (CRT). The authors concluded that baseline CD163 expression predicts for an unfavourable clinical outcome in HNSCC after definitive CRT.
The role of a Mediterranean diet on the risk of oral and pharyngeal cancer	British Journal of Cancer, Vol. 111, No. 5, pages 981-986.	26 August	Data analysis from a case-control study using the Mediterranean Diet Score (MDS). This particular study provided strong evidence of a beneficial role of the Mediterranean diet on oral and pharyngeal cancer (OCP) cancer.
Prognostic significance of p62/SQSTM1 subcellular localization and LC3B in oral squamous cell carcinoma	British Journal of Cancer, Vol. 111, No. 5, pages 944-954.	26 August	Study which compared autophagy in oral squamous cell carcinomas (OSCCs), verrucous hyperplasias, and normal oral mucosas, and to inspect the prognostic role of autophagy in OSCCs. The analysis suggests autophagy impairment contributes to cancer progression in advanced OSCCs.
Identification of chemoresistant factors by protein expression analysis with iTRAQ for head and neck carcinoma	British Journal of Cancer, Vol. 111, No. 4, pages 799-806.	12 August	Article which investigated chemoresistance factors by comprehensive analyses at the protein level. Thirteen multiple-drug resistance proteins were identified, as well as seven proteins with specific resistance to cisplatin, including α -enolase.
The roles of HOXD10 in the development and progression of head and neck squamous cell carcinoma (HNSCC)	British Journal of Cancer, Vol. 111, No. 4, pages 807-816.	12 August	Article where HOXD10 expression was assessed by qPCR and immunoblotting <i>in vitro</i> and by immunohistochemistry (IHC) in tissues. HOXD10 expression varies by stage of disease and produces differential effects - HOXD10 expression was low in NOKs, high in most primary tumour cells, and low in lymph node metastasis cells.

Cont. overleaf

Visit www.gelclair.co.uk for free sample packs and more information on Gelclair





Literary Review, cont.



July to October 2014

Title	Publication	Date	Overview
CD10 as a novel marker of therapeutic resistance and cancer stem cells in head and neck squamous cell carcinoma	British Journal of Cancer, Vol. 111, No. 3, pages 506-514.	29 July	Cancer stem cells (CSCs) are responsible for treatment failure but their roles in resistance are not well established in head and neck squamous cell carcinoma (HNSCC). Three HNSCC cell lines were treated with cisplatin or radiation. The study concludes that CD10 is associated with therapeutic resistance and CSC-like properties of HNSCC and may serve as a target molecule in the treatment of refractory HNSCC.
Outpatient follow-up appointments for patients having curative treatment for cancer of the head and neck: are the current arrangements in need of change?	British Journal of Oral and Maxillofacial Surgery, Vol. 52, No. 8, pages 681-687.	October	Article which reviewed the frequency/duration of review appointments for head and neck cancer patients. The authors concluded that the number/timing of follow-up visits is adequate for stage II-IV disease patients. Those with stage I disease may be considered for discharge after the third year if they are told about the risk factors, signs and symptoms of recurrent disease, and surveillance in primary care.
Quality of life, psychological wellbeing and treatment needs of trauma and head and neck cancer patients	British Journal of Oral and Maxillofacial Surgery, Vol. 52, No. 6, pages 513-517.	July	Self-reported questionnaire results from patients treated for trauma or cancer of the head and neck to assess psychological distress. 39% of patients showed high levels of depressive symptoms and 43% reported high levels of anxiety. 40% of those with high levels of psychological distress were willing to consider psychological support.
Cryotherapy Effect on Oral Mucositis Severity Among Recipients of Bone Marrow Transplantation: A Literature Review	Clinical Journal of Oncology Nursing, Vol. 18, No. 4, pages E84-E87.	August	Article which looks at oral mucositis - a distressing toxic effect of cancer therapy and one of the major side effects of the myeloablative conditioning used to prepare patients for bone marrow transplantation (BMT). Using a literature search of six articles, the author also reviews the use of oral cryotherapy to prevent and manage oral mucositis.

Cont. overleaf

Visit www.gelclair.co.uk for free sample packs and more information on Gelclair





Literary Review, cont.



July to October 2014

Title	Publication	Date	Overview
E-cigarettes have little benefit for smokers with cancer, study finds	Cancer Nursing Practice, Vol. 13, No. 8, page 7.	October	A study of cancer patients who smoke has found that those using e-cigarettes in addition to traditional cigarettes were more nicotine dependent and were equally or less likely to have stopped smoking traditional cigarettes compared with non-users. At enrolment, e-cigarette users were more nicotine dependent than non-users, had more previous attempts at quitting and were more likely to be diagnosed with lung or head and neck cancers.
Effectiveness of prophylactic gastrostomy in patients having treatment for head and neck cancer	Cancer Nursing Practice, Vol. 13, No. 8, pages 21-30.	October	Literature review to compare the effectiveness of prophylactic gastrostomy vs. no prophylactic gastrostomy in patients with head and neck cancer for the outcomes of treatment interruptions, unplanned admissions and weight changes, due to nutritional reasons. Analysis showed prophylactic gastrostomy decreases the number of unplanned admissions and may reduce weight loss.
Research reveals extent of difficulties brought about by loneliness	Cancer Nursing Practice, Vol. 13, No. 7, page 7.	September	Research from Macmillan Cancer Support has found that lonely cancer patients are three times more likely to struggle with their treatment plans than those supported by friends or family.
How patients' feedback was used to redesign a head and neck service	Cancer Nursing Practice, Vol. 13, No. 6, pages 20-26.	July	Article detailing a redesign project for head and neck cancer follow-up services in a Scottish cancer centre. Patients who had completed treatment, and their carers, attended a patient experience event. Findings revealed a range of unmet needs for information and support, as well as challenges experienced in the integration and organisation of services. The events led to fundamental changes, enabling a more patient-centred service.
Dysphagia and swallowing disorders	Nursing in Practice, No 80.	September /October	Article which looks at symptoms and risk factors for dysphagia along with management and treatment options. It also looks at living with the condition, which includes social and quality of life issues that may arise.

Visit www.gelclair.co.uk for free sample packs and more information on Gelclair



Under the license of
Helsinn Healthcare SA, Switzerland.



Take away the pain of oral mucositis...



with

 **gelclair**[®]



- Gelclair is a **highly effective barrier-forming gel**¹⁻³ specially formulated to aid in the management of lesions of the oral mucosa.
 - Has been shown to reduce pain in 86% of patients.⁴
- Gelclair is available in easy to use sachets.
- **Starter packs** are available to order free of charge from our website.



In an online survey, 92% of patients are satisfied with Gelclair and would recommend to other oral mucositis patients.⁵

For more information on Gelclair or to request a free starter pack, as well as access to helpful resources including patient case study videos, please visit www.gelclair.co.uk, call our Customer Services team on **01249 466 966**, or email us at medinfo@alliancepharma.co.uk

References: 1. Innocenti M et al. *J Pain Symptom Manage* 2002; 24(5): 456-457. 2. McLean M. Poster presented at the British Association of Head and Neck Oncology Nurses National Study Day on Sharing Good Practice in Head and Neck Cancer Nursing, 12 June 2009. 3. Gibson et al. Presented at SIOP 2010. 4. Kantardžić N et al., *The Internet Journal of Oncology* 2009; 6(2). 5. Data on file: Patient online feedback. Correct as of January 2014.

 **ALLIANCE**

Medical device incidents should be reported. Reporting information can be found at www.mhra.gov.uk
Adverse events should also be reported to Pharmacovigilance at Alliance Pharmaceuticals
(tel: 01249 466 966, email: pharmacovigilance@alliancepharma.co.uk)


It's got oral mucositis covered

AL/1687/03.14/0.1. Date of preparation: July 2014